Alzheimer's disease is debilitating neurodegenerative disorder in the elderly. Current therapy relies on administration of acetylcholinesterase inhibitors (AChEIs) -donepezil, rivastigmine, galantamine, and N-methyl-d-aspartate receptor antagonist memantine. However, their therapeutic effect is only short-term and stabilizes cognitive functions for up to 2 years. Given this drawback together with other pathological hallmarks of the disease taken into consideration, novel approaches have recently emerged to better cope with AD onset or its progression. One such strategy implies broadening the biological profile of AChEIs into so-called multi-target directed ligands (MTDLs). In this review article, we made comprehensive literature survey emphasising on donepezil template which was structurally converted into plethora of MTLDs preserving anti-cholinesterase effect and, at the same time, escalating the anti-oxidant potential, which was reported as a crucial role in the pathogenesis of the Alzheimer's disease.

b National Institute of Mental Health Klecany Czech Republic

Biomedical Research Centre University Hospital Hradec Kralove Hradec Kralove Czech Republic

c Department of Toxicology and Military Pharmacy Faculty of Military Health Sciences Hradec Kralove Czech Republic

Department of Chemistry University of Hradec Kralove Hradec Kralove Czech Republic

Zobrazit více v PubMed

Sanabria-Castro A, Alvarado-Echeverría I, Monge-Bonilla C. Molecular pathogenesis of Alzheimer's disease: an update. Ann Neurosci 2017;24:46–54. PubMed PMC

Ritchie CW, Molinuevo JL, Truyen L, et al. . Development of interventions for the secondary prevention of Alzheimer’s dementia: the European Prevention of Alzheimer’s Dementia (EPAD) project. Lancet Psychiatry 2016;3:179–86. PubMed

Marešová P, Mohelská H, Dolejš J, Kuča K. Socio-economic aspects of Alzheimer's disease. Curr Alzheimer Res 2015;12:903–11. PubMed

Bartus RT, Dean RL, Beer B, Lippa AS.. The cholinergic hypothesis of geriatric memory dysfunction. Science 1982;217:408–14. PubMed

Francis P, Palmer A, Snape M, Wilcock G. The cholinergic hypothesis of Alzheimer's disease: a review of progress. J Neurol Neurosurg Psychiatry 1999;66:137–47. PubMed PMC

Francis PT. The interplay of neurotransmitters in Alzheimer's disease. CNS Spectr 2005;10:6–9. PubMed

Mann DM, Yates PO, Marcyniuk B.. Dopaminergic neurotransmitter systems in Alzheimer’s disease and in Down’s syndrome at middle age. J Neurol Neurosurg Psychiatry 1987;50:341–4. PubMed PMC

Rodríguez JJ, Noristani HN, Verkhratsky A. The serotonergic system in ageing and Alzheimer's disease. Prog Neurobiol 2012;99:15–41. PubMed

Zemek F, Drtinova L, Nepovimova E, et al. . Outcomes of Alzheimer’s disease therapy with acetylcholinesterase inhibitors and memantine. Expert Opin Drug Saf 2014;13:759–74. PubMed

Nordberg A, Ballard C, Bullock R, et al. . A review of butyrylcholinesterase as a therapeutic target in the treatment of Alzheimer’s disease. Prim Care Companion CNS Disord 2013;15. doi:10.4088/PCC.12r01412 PubMed DOI PMC

Spilovska K, Korabecny J, Nepovimova E, et al. . Multitarget tacrine hybrids with neuroprotective properties to confront Alzheimer’s disease. Curr Top Med Chem 2017;17:1006–26. PubMed

Spilovska K, Zemek F, Korabecny J, et al. . Adamantane - a lead structure for drugs in clinical practice. Curr Med Chem 2016;23:3245–66. PubMed

Farlow MR, Graham SM, Alva G. Memantine for the treatment of Alzheimer's disease: tolerability and safety data from clinical trials. Drug Saf 2008;31:577–85. PubMed

Horak M, Holubova K, Nepovimova E, et al. . The pharmacology of tacrine at N-methyl-d-aspartate receptors. Prog Neuropsychopharmacol Biol Psychiatry 2017;75:54–62. PubMed

Hynd MR, Scott HL, Dodd PR. Glutamate-mediated excitotoxicity and neurodegeneration in Alzheimer's disease. Neurochem Int 2004;45:583–95. PubMed

Hamley IW. The amyloid beta peptide: a chemist's perspective. Role in Alzheimer's and fibrillization. Chem Rev 2012;112:5147–92. PubMed

Barage SH, Sonawane KD. Amyloid cascade hypothesis: pathogenesis and therapeutic strategies in Alzheimer's disease. Neuropeptides 2015;52:1–18. PubMed

Giacobini E, Gold G.. Alzheimer disease therapy–moving from amyloid-β to tau. Nat Rev Neurol 2013;9:677–86. PubMed

Avila J, Lucas JJ, Perez M, Hernandez F.. Role of tau protein in both physiological and pathological conditions. Physiol Rev 2004;84:361–84. PubMed

Forman MS, Trojanowski JQ, Lee VM-Y.. Neurodegenerative diseases: a decade of discoveries paves the way for therapeutic breakthroughs. Nat Med 2004;10:1055–63. PubMed

Gandhi S, Abramov AY.. Mechanism of oxidative stress in neurodegeneration. Oxid Med Cell Longev 2012;2012:428010. PubMed PMC

Bolisetty S, Jaimes EA.. Mitochondria and reactive oxygen species: physiology and pathophysiology. Int J Mol Sci 2013;14:6306–44. PubMed PMC

Kim GH, Kim JE, Rhie SJ, Yoon S.. The role of oxidative stress in neurodegenerative diseases. Exp Neurobiol 2015;24:325–40. PubMed PMC

Dasuri K, Zhang L, Keller JN.. Oxidative stress, neurodegeneration, and the balance of protein degradation and protein synthesis. Free Radic Biol Med 2013;62:170–85. PubMed

Patten DA, Germain M, Kelly MA, Slack RS.. Reactive oxygen species: stuck in the middle of neurodegeneration. J Alzheimers Dis 2010;20 Suppl 2:S357–S67. PubMed

Wang X, Michaelis EK.. Selective neuronal vulnerability to oxidative stress in the brain. Front Aging Neurosci 2010;2:12. PubMed PMC

Radi E, Formichi P, Battisti C, Federico A.. Apoptosis and oxidative stress in neurodegenerative diseases. J Alzheimers Dis 2014;42 Suppl 3:S125–S52. PubMed

Zhao Y, Zhao B.. Oxidative stress and the pathogenesis of Alzheimer’s disease. Oxid Med Cell Longev 2013;2013:316523. PubMed PMC

Praticò D. Oxidative stress hypothesis in Alzheimer’s disease: a reappraisal. Trends Pharmacol Sci 2008;29:609–15. PubMed

Firuzi O, Miri R, Tavakkoli M, Saso L.. Antioxidant therapy: current status and future prospects. Curr Med Chem 2011;18:3871–88. PubMed

Murphy MP. Antioxidants as therapies: can we improve on nature?. Free Radic Biol Med 2014;66:20–3. PubMed

Nepovimova E, Korabecny J, Dolezal R, et al. . Tacrine-trolox hybrids: a novel class of centrally active, nonhepatotoxic multi-target-directed ligands exerting anticholinesterase and antioxidant activities with low in vivo toxicity. J Med Chem 2015;58:8985–9003. PubMed

Rosini M, Andrisano V, Bartolini M, et al. . Rational approach to discover multipotent anti-Alzheimer drugs. J Med Chem 2005;48:360–3. PubMed

Pinchuk I, Shoval H, Dotan Y, Lichtenberg D.. Evaluation of antioxidants: scope, limitations and relevance of assays. Chem Phys Lipids 2012;165:638–47. PubMed

Alam MN, Bristi NJ, Rafiquzzaman M.. Review on in vivo and in vitro methods evaluation of antioxidant activity. Saudi Pharm J 2013;21:143–52. PubMed PMC

Balasaheb Nimse S, Pal D.. Free radicals, natural antioxidants, and their reaction mechanisms. RSC Adv 2015;5:27986–8006.

Pisoschi AM, Negulescu GP.. Methods for total antioxidant activity determination: a review. Biochem Anal Biochem 2011;1:106.

Karadag A, Ozcelik B, Saner S.. Review of Methods to Determine Antioxidant Capacities. Food Anal Methods 2009;2:41–60.

Apak R, Gorinstein S, Böhm V, et al. . Methods of measurement and evaluation of natural antioxidant capacity/activity (IUPAC Technical Report). Pure Appl Chem 2013;85:957–98.

Huang D, Ou B, Prior RL.. The chemistry behind antioxidant capacity assays. J Agric Food Chem 2005;53:1841–56. PubMed

Benzie IF, Strain JJ. The ferric reducing ability of plasma (FRAP) as a measure of “antioxidant power”: the FRAP assay. Anal Biochem 1996;239:70–6. PubMed

Özyürek M, Güçlü K, Tütem E, et al. . A comprehensive review of CUPRAC methodology. Anal Methods 2011;3:2439–53.

Re R, Pellegrini N, Proteggente A, et al. . Antioxidant activity applying an improved ABTS radical cation decolorization assay. Free Radic Biol Med 1999;26:1231–7. PubMed

van den Berg R, Haenen GRMM, van den Berg H, Bast A.. Applicability of an improved Trolox equivalent antioxidant capacity (TEAC) assay for evaluation of antioxidant capacity measurements of mixtures. Food Chem 1999;66:511–7.

Sharma OP, Bhat TK.. DPPH antioxidant assay revisited. Food Chem 2009;113:1202–5.

Shahidi F, Zhong Y.. Measurement of antioxidant activity. J Funct Foods 2015;18:757–81.

Niki E. Free radical initiators as source of water- or lipid-soluble peroxyl radicals. Methods Enzymol 1990;186:100–8. PubMed

Cao G, Prior RL.. Measurement of oxygen radical absorbance capacity in biological samples. Methods Enzymol 1999;299:50–62. PubMed

López-Alarcón C, Denicola A.. Evaluating the antioxidant capacity of natural products: a review on chemical and cellular-based assays. Anal Chim Acta 2013;763:1–10. PubMed

Peng X-M, Damu GLV, Zhou C-H.. Current developments of coumarin compounds in medicinal chemistry. Curr Pharm Des 2013;19:3884–930. PubMed

Venugopala KN, Rashmi V, Odhav B.. Review on natural coumarin lead compounds for their pharmacological activity. BioMed Res Int 2013;2013:963248. PubMed PMC

Anand P, Singh B, Singh N. A review on coumarins as acetylcholinesterase inhibitors for Alzheimer's disease. Bioorg Med Chem 2012;20:1175–80. PubMed

Castro A, Martinez A. Peripheral and dual binding site acetylcholinesterase inhibitors: implications in treatment of Alzheimer's disease. Mini Rev Med Chem 2001;1:267–72. PubMed

Radić Z, Reiner E, Taylor P.. Role of the peripheral anionic site on acetylcholinesterase: inhibition by substrates and coumarin derivatives. Mol Pharmacol 1991;39:98–104. PubMed

Radić Z, Reiner E, Simeon V.. Binding sites on acetylcholinesterase for reversible ligands and phosphorylating agents. A theoretical model tested on haloxon and phosphostigmine. Biochem Pharmacol 1984;33:671–7. PubMed

Catto M, Nicolotti O, Leonetti F, et al. . Structural insights into monoamine oxidase inhibitory potency and selectivity of 7-substituted coumarins from ligand- and target-based approaches. J Med Chem 2006;49:4912–25. PubMed

Gnerre C, Catto M, Leonetti F, et al. . Inhibition of monoamine oxidases by functionalized coumarin derivatives: biological activities, QSARs, and 3D-QSARs. J Med Chem 2000;43:4747–58. PubMed

Pisani L, Catto M, Giangreco I, et al. . Design, synthesis, and biological evaluation of coumarin derivatives tethered to an edrophonium-like fragment as highly potent and selective dual binding site acetylcholinesterase inhibitors. ChemMedChem 2010;5:1616–30. PubMed

Pisani L, Muncipinto G, Miscioscia TF, et al. . Discovery of a novel class of potent coumarin monoamine oxidase B inhibitors: development and biopharmacological profiling of 7-[(3-chlorobenzyl)oxy]-4-[(methylamino)methyl]-2H-chromen-2-one methanesulfonate (NW-1772) as a highly potent, selective, reversible, and orally active monoamine oxidase B inhibitor. J Med Chem 2009;52:6685–706. PubMed

Catto M, Pisani L, Leonetti F, et al. . Design, synthesis and biological evaluation of coumarin alkylamines as potent and selective dual binding site inhibitors of acetylcholinesterase. Bioorg Med Chem 2013;21:146–52. PubMed

Khoobi M, Emami S, Dehghan G, et al. . Synthesis and free radical scavenging activity of coumarin derivatives containing a 2-methylbenzothiazoline motif. Arch Pharm (Weinheim) 2011;344:588–94. PubMed

Khoobi M, Foroumadi A, Emami S, et al. . Coumarin-based bioactive compounds: facile synthesis and biological evaluation of coumarin-fused 1,4-thiazepines. Chem Biol Drug Des 2011;78:580–6. PubMed

Khoobi M, Alipour M, Zarei S, et al. . A facile route to flavone and neoflavone backbones via a regioselective palladium catalyzed oxidative Heck reaction. Chem Commun Camb Engl 2012;48:2985–7. PubMed

Khoobi M, Ramazani A, Foroumadi A, et al. . Highly cis-diastereoselective synthesis of coumarin-based 2,3-disubstituted dihydrobenzothiazines by organocatalysis. Helv Chim Acta 2012;95:660–71.

Khoobi M, Ramazani A, Foroumadi AR, et al. . Efficient microwave-assisted synthesis of 3-benzothiazolo and 3-benzothiazolino coumarin derivatives catalyzed by heteropoly acids. J Iran Chem Soc 2012;8:1036–42.

Nadri H, Pirali-Hamedani M, Shekarchi M, et al. . Design, synthesis and anticholinesterase activity of a novel series of 1-benzyl-4-((6-alkoxy-3-oxobenzofuran-2(3H)-ylidene) methyl) pyridinium derivatives. Bioorg Med Chem 2010;18:6360–6. PubMed

Alipour M, Khoobi M, Foroumadi A, et al. . Novel coumarin derivatives bearing N-benzyl pyridinium moiety: potent and dual binding site acetylcholinesterase inhibitors. Bioorg Med Chem 2012;20:7214–22. PubMed

Razavi SF, Khoobi M, Nadri H, et al. . Synthesis and evaluation of 4-substituted coumarins as novel acetylcholinesterase inhibitors. Eur J Med Chem 2013;64:252–9. PubMed

Alipour M, Khoobi M, Nadri H, et al. . Synthesis of some new 3-coumaranone and coumarin derivatives as dual inhibitors of acetyl- and butyrylcholinesterase. Arch Pharm (Weinheim) 2013;346:577–87. PubMed

Pajouhesh H, Lenz GR.. Medicinal chemical properties of successful central nervous system drugs. NeuroRx J Am Soc Exp Neurother 2005;2:541–53. PubMed PMC

Asadipour A, Alipour M, Jafari M, et al. . Novel coumarin-3-carboxamides bearing N-benzylpiperidine moiety as potent acetylcholinesterase inhibitors. Eur J Med Chem 2013;70:623–30. PubMed

Khoobi M, Alipour M, Sakhteman A, et al. . Design, synthesis, biological evaluation and docking study of 5-oxo-4,5-dihydropyrano[3,2-c]chromene derivatives as acetylcholinesterase and butyrylcholinesterase inhibitors. Eur J Med Chem 2013;68:260–9. PubMed

Khoobi M, Alipour M, Moradi A, et al. . Design, synthesis, docking study and biological evaluation of some novel tetrahydrochromeno [3’,4’:5,6]pyrano[2,3-b]quinolin-6(7H)-one derivatives against acetyl- and butyrylcholinesterase. Eur J Med Chem 2013;68:291–300. PubMed

Pudlo M, Luzet V, Ismaïli L, et al. . Quinolone-benzylpiperidine derivatives as novel acetylcholinesterase inhibitor and antioxidant hybrids for Alzheimer disease. Bioorg Med Chem 2014;22:2496–507. PubMed

Detsi A, Bouloumbasi D, Prousis KC, et al. . Design and synthesis of novel quinolinone-3-aminoamides and their alpha-lipoic acid adducts as antioxidant and anti-inflammatory agents. J Med Chem 2007;50:2450–8. PubMed

Naito Y, Yoshikawa T, Tanigawa T, et al. . Hydroxyl radical scavenging by rebamipide and related compounds: electron paramagnetic resonance study. Free Radic Biol Med 1995;18:117–23. PubMed

Pouységu L, Deffieux D, Malik G, et al. . Synthesis of ellagitannin natural products. Nat Prod Rep 2011;28:853–74. PubMed

Seeram NP, Henning SM, Zhang Y, et al. . Pomegranate juice ellagitannin metabolites are present in human plasma and some persist in urine for up to 48 hours. J Nutr 2006;136:2481–5. PubMed

Gulcan HO, Unlu S, Esiringu I, et al. . Design, synthesis and biological evaluation of novel 6H-benzo[c]chromen-6-one, and 7,8,9,10-tetrahydro-benzo[c]chromen-6-one derivatives as potential cholinesterase inhibitors. Bioorg Med Chem 2014;22:5141–54. PubMed

Sgarbossa A, Giacomazza D, di Carlo M. Ferulic acid: a hope for alzheimer's disease therapy from plants. Nutrients 2015;7:5764–82. PubMed PMC

Benchekroun M, Bartolini M, Egea J, et al. . Novel tacrine-grafted Ugi adducts as multipotent anti-Alzheimer drugs: a synthetic renewal in tacrine-ferulic acid hybrids. ChemMedChem 2015;10:523–39. PubMed

Chen Y, Sun J, Fang L, et al. . Tacrine–ferulic acid–nitric oxide (NO) donor trihybrids as potent, multifunctional acetyl- and butyrylcholinesterase inhibitors. J Med Chem 2012;55:4309–21. PubMed

Fang L, Kraus B, Lehmann J, et al. . Design and synthesis of tacrine–ferulic acid hybrids as multi-potent anti-Alzheimer drug candidates. Bioorg Med Chem Lett 2008;18:2905–9. PubMed

Benchekroun M, Ismaili L, Pudlo M, et al. . Donepezil-ferulic acid hybrids as anti-Alzheimer drugs. Future Med Chem 2015;7:15–21. PubMed

Sang Z, Pan W, Wang K, et al. . Design, synthesis and evaluation of novel ferulic acid-O-alkylamine derivatives as potential multifunctional agents for the treatment of Alzheimer’s disease. Eur J Med Chem 2017;130:379–92. PubMed

Verghese J. Isolation of curcumin from Curcuma longa L. rhizome. Flavour Fragr J 1993;8:315–9.

Katsuyama Y, Kita T, Funa N, Horinouchi S.. Curcuminoid biosynthesis by two type III polyketide synthases in the herb Curcuma longa . J Biol Chem 2009;284:11160–70. PubMed PMC

Ammon HP, Wahl MA.. Pharmacology of Curcuma longa . Planta Med 1991;57:1–7. PubMed

Wang Y-J, Thomas P, Zhong J-H, et al. . Consumption of grape seed extract prevents amyloid-beta deposition and attenuates inflammation in brain of an Alzheimer’s disease mouse. Neurotox Res 2009;15:3–14. PubMed

Dairam A, Fogel R, Daya S, Limson JL.. Antioxidant and iron-binding properties of curcumin, capsaicin, and S-allylcysteine reduce oxidative stress in rat brain homogenate. J Agric Food Chem 2008;56:3350–6. PubMed

Park S-Y, Kim DSHL.. Discovery of natural products from Curcuma longa that protect cells from beta-amyloid insult: a drug discovery effort against Alzheimer’s disease. J Nat Prod 2002;65:1227–31. PubMed

Kim H, Park B-S, Lee K-G, et al. . Effects of naturally occurring compounds on fibril formation and oxidative stress of beta-amyloid. J Agric Food Chem 2005;53:8537–41. PubMed

Shimmyo Y, Kihara T, Akaike A, et al. . Epigallocatechin-3-gallate and curcumin suppress amyloid beta-induced beta-site APP cleaving enzyme-1 upregulation. Neuroreport 2008;19:1329–33. PubMed

Derosa G, Maffioli P, Simental-Mendía LE, et al. . Effect of curcumin on circulating interleukin-6 concentrations: a systematic review and meta-analysis of randomized controlled trials. Pharmacol Res 2016;111:394–404. PubMed

Tang M, Taghibiglou C. The mechanisms of action of curcumin in Alzheimer's disease. J Alzheimers Dis 2017;58:1003–16. PubMed

Mishra CB, Manral A, Kumari S, et al. . Design, synthesis and evaluation of novel indandione derivatives as multifunctional agents with cholinesterase inhibition, anti-β-amyloid aggregation, antioxidant and neuroprotection properties against Alzheimer’s disease. Bioorg Med Chem 2016;24:3829–41. PubMed

Mishra CB, Kumari S, Manral A, et al. . Design, synthesis, in-silico and biological evaluation of novel donepezil derivatives as multi-target-directed ligands for the treatment of Alzheimer’s disease. Eur J Med Chem 2017;125:736–50. PubMed

Yan J, Hu J, Liu A, et al. . Design, synthesis, and evaluation of multitarget-directed ligands against Alzheimer’s disease based on the fusion of donepezil and curcumin. Bioorg Med Chem 2017;25:2946–55. PubMed

Szutowicz A, Bielarczyk H, Zyśk M, et al. . Early and late pathomechanisms in Alzheimer's disease: from zinc to amyloid-β neurotoxicity. Neurochem Res 2017;42:891–904. PubMed PMC

Ritchie CW, Bush AI, Mackinnon A, et al. . Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. Arch Neurol 2003;60:1685–91. PubMed

Sampson EL, Jenagaratnam L, McShane R.. Metal protein attenuating compounds for the treatment of Alzheimer’s dementia. Cochrane Database Syst Rev 2012;2012:CD005380. PubMed PMC

Dias KST, de Paula CT, Dos Santos T, et al. . Design, synthesis and evaluation of novel feruloyl-donepezil hybrids as potential multitarget drugs for the treatment of Alzheimer’s disease. Eur J Med Chem 2017;130:440–57. PubMed

Cai Y-Z, Mei S, null, Jie X, null, et al. Structure-radical scavenging activity relationships of phenolic compounds from traditional Chinese medicinal plants. Life Sci 2006;78:2872–88. PubMed

Allmang C, Wurth L, Krol A.. The selenium to selenoprotein pathway in eukaryotes: more molecular partners than anticipated. Biochim Biophys Acta 2009;1790:1415–23. PubMed

Berr C, Nicole A, Godin J, et al. . Selenium and oxygen-metabolizing enzymes in elderly community residents: a pilot epidemiological study. J Am Geriatr Soc 1993;41:143–8. PubMed

Wilson SR, Zucker PA, Huang RRC, Spector A.. Development of synthetic compounds with glutathione peroxidase activity. J Am Chem Soc 1989;111:5936–9.

Xie L, Zheng W, Xin N, et al. . Ebselen inhibits iron-induced tau phosphorylation by attenuating DMT1 up-regulation and cellular iron uptake. Neurochem Int 2012;61:334–40. PubMed

Luo Z, Sheng J, Sun Y, et al. . Synthesis and evaluation of multi-target-directed ligands against Alzheimer’s disease based on the fusion of donepezil and ebselen. J Med Chem 2013;56:9089–99. PubMed

Luo Z, Liang L, Sheng J, et al. . Synthesis and biological evaluation of a new series of ebselen derivatives as glutathione peroxidase (GPx) mimics and cholinesterase inhibitors against Alzheimer’s disease. Bioorg Med Chem 2014;22:1355–61. PubMed

Meng F-C, Mao F, Shan W-J, et al. . Design, synthesis, and evaluation of indanone derivatives as acetylcholinesterase inhibitors and metal-chelating agents. Bioorg Med Chem Lett 2012;22:4462–6. PubMed

Nadri H, Pirali-Hamedani M, Moradi A, et al. . 5,6-Dimethoxybenzofuran-3-one derivatives: a novel series of dual Acetylcholinesterase/Butyrylcholinesterase inhibitors bearing benzyl pyridinium moiety. Daru J Fac Pharm Tehran Univ Med Sci 2013;21:15. PubMed PMC

Akrami H, Mirjalili BF, Khoobi M, et al. . Indolinone-based acetylcholinesterase inhibitors: synthesis, biological activity and molecular modeling. Eur J Med Chem 2014; 84:375–81. PubMed

Cheng F, Li W, Zhou Y, et al. . admetSAR: a comprehensive source and free tool for assessment of chemical ADMET properties. J Chem Inf Model 2012;52:3099–105. PubMed

Baharloo F, Moslemin MH, Nadri H, et al. . Benzofuran-derived benzylpyridinium bromides as potent acetylcholinesterase inhibitors. Eur J Med Chem 2015;93:196–201. PubMed

Huang L, Lu C, Sun Y, et al. . Multitarget-directed benzylideneindanone derivatives: anti-β-amyloid (Aβ) aggregation, antioxidant, metal chelation, and monoamine oxidase B (MAO-B) inhibition properties against Alzheimer’s disease. J Med Chem 2012;55:8483–92. PubMed

Huang L, Miao H, Sun Y, et al. . Discovery of indanone derivatives as multi-target-directed ligands against Alzheimer’s disease. Eur J Med Chem 2014;87:429–39. PubMed

Yerdelen KO, Koca M, Anil B, et al. . Synthesis of donepezil-based multifunctional agents for the treatment of Alzheimer's disease. Bioorg Med Chem Lett 2015;25:5576–82. PubMed

Koca M, Yerdelen KO, Anil B, et al. . Design, synthesis and biological activity of 1H-indene-2-carboxamides as multi-targeted anti-Alzheimer agents. J Enzyme Inhib Med Chem 2016;31:13–23. PubMed

Yerdelen KO, Tosun E.. Synthesis, docking and biological evaluation of oxamide and fumaramide analogs as potential AChE and BuChE inhibitors. Med Chem Res 2015;24:588–602.

Lan J-S, Zhang T, Liu Y, et al. . Design, synthesis and biological activity of novel donepezil derivatives bearing N-benzyl pyridinium moiety as potent and dual binding site acetylcholinesterase inhibitors. Eur J Med Chem 2017;133:184–96. PubMed

Bohn P, Gourand F, Papamicaël C, et al. . Dihydroquinoline carbamate derivatives as “bio-oxidizable” prodrugs for brain delivery of acetylcholinesterase inhibitors: [11C] radiosynthesis and biological evaluation. ACS Chem Neurosci 2015;6:737–44. PubMed

Peauger L, Azzouz R, Gembus V, et al. . Donepezil-based central acetylcholinesterase inhibitors by means of a ‘bio-oxidizable’ prodrug strategy: design, synthesis, and in vitro biological evaluation. J Med Chem 2017;60:5909–26. PubMed

Di L, Kerns EH, Fan K, et al. . High throughput artificial membrane permeability assay for blood-brain barrier. Eur J Med Chem 2003;38:223–32. PubMed

Lemes LFN, de Andrade Ramos G, de Oliveira AS, et al. . Cardanol-derived AChE inhibitors: towards the development of dual binding derivatives for Alzheimer’s disease. Eur J Med Chem 2016;108:687–700. PubMed

Miller E, Morel A, Saso L, Saluk J.. Melatonin redox activity. Its potential clinical applications in neurodegenerative disorders. Curr Top Med Chem 2015;15:163–9. PubMed

Li X-C, Wang Z-F, Zhang J-X, et al. . Effect of melatonin on calyculin A-induced tau hyperphosphorylation. Eur J Pharmacol 2005;510:25–30. PubMed

Lahiri DK. Melatonin affects the metabolism of the beta-amyloid precursor protein in different cell types. J Pineal Res 1999;26:137–46. PubMed

Rosales-Corral S, Tan D-X, Reiter RJ, et al. . Orally administered melatonin reduces oxidative stress and proinflammatory cytokines induced by amyloid-beta peptide in rat brain: a comparative, in vivo study versus vitamin C and E. J Pineal Res 2003;35:80–4. PubMed

Wu Y-H, Swaab DF. The human pineal gland and melatonin in aging and Alzheimer's disease. J Pineal Res 2005;38:145–52. PubMed

Ramos E, Egea J, de Los Ríos C, et al. . Melatonin as a versatile molecule to design novel multitarget hybrids against neurodegeneration. Future Med Chem 2017;9:765–80. PubMed

Wang J, Wang Z-M, Li X-M, et al. . Synthesis and evaluation of multi-target-directed ligands for the treatment of Alzheimer's disease based on the fusion of donepezil and melatonin. Bioorg Med Chem 2016;24:4324–38. PubMed

Luo X-T, Wang C-M, Liu Y, Huang Z-G.. New multifunctional melatonin-derived benzylpyridinium bromides with potent cholinergic, antioxidant, and neuroprotective properties as innovative drugs for Alzheimer’s disease. Eur J Med Chem 2015;103:302–11. PubMed

Prati F, Bergamini C, Fato R, et al. . Novel 8-hydroxyquinoline derivatives as multitarget compounds for the treatment of Alzheimer’s disease. ChemMedChem 2016;11:1284–95. PubMed

Adlard PA, Cherny RA, Finkelstein DI, et al. . Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Abeta. Neuron 2008;59:43–55. PubMed

Nguyen T, Hamby A, Massa SM.. Clioquinol down-regulates mutant huntingtin expression in vitro and mitigates pathology in a Huntington’s disease mouse model. Proc Natl Acad Sci USA 2005;102:11840–5. PubMed PMC

Simoni E, Caporaso R, Bergamini C, et al. . Polyamine conjugation as a promising strategy to target amyloid aggregation in the framework of Alzheimer’s disease. ACS Med Chem Lett 2016;7:1145–50. PubMed PMC

Wu M-Y, Esteban G, Brogi S, et al. . Donepezil-like multifunctional agents: design, synthesis, molecular modeling and biological evaluation. Eur J Med Chem 2016;121:864–79. PubMed

Korábečný J, Nepovimová E, Cikánková T, et al. . Newly developed drugs for Alzheimer’s disease in relation to energy metabolism, cholinergic and monoaminergic neurotransmission. Neuroscience 2018;370:191–206. PubMed

Wang Z-M, Cai P, Liu Q-H, et al. . Rational modification of donepezil as multifunctional acetylcholinesterase inhibitors for the treatment of Alzheimer’s disease. Eur J Med Chem 2016;123:282–97. PubMed

Arce MP, Rodríguez-Franco MI, González-Muñoz GC, et al. . Neuroprotective and cholinergic properties of multifunctional glutamic acid derivatives for the treatment of Alzheimer’s disease. J Med Chem 2009;52:7249–57. PubMed

Monjas L, Arce MP, León R, et al. . Enzymatic and solid-phase synthesis of new donepezil-based L- and d-glutamic acid derivatives and their pharmacological evaluation in models related to Alzheimer’s disease and cerebral ischemia. Eur J Med Chem 2017;130:60–72. PubMed

Maroto M, de Diego AMG, Albiñana E, et al. . Multi-target novel neuroprotective compound ITH33/IQM9.21 inhibits calcium entry, calcium signals and exocytosis. Cell Calcium 2011;50:359–69. PubMed

Lorrio S, Gómez-Rangel V, Negredo P, et al. . Novel multitarget ligand ITH33/IQM9.21 provides neuroprotection in in vitro and in vivo models related to brain ischemia. Neuropharmacology 2013;67:403–11. PubMed

Moreno-Ortega AJ, Al-achbili LM, Alonso E, et al. . Neuroprotective effect of the novel compound ITH33/IQM9.21 against oxidative stress and Na+ and Ca2+ overload in motor neuron-like NSC-34 cells. Neurotox Res 2016;30:380–91. PubMed

Di Domenico F, Barone E, Perluigi M, Butterfield DA.. Strategy to reduce free radical species in Alzheimer’s disease: an update of selected antioxidants. Expert Rev Neurother 2015;15:19–40. PubMed

Castañeda-Arriaga R, Alvarez-Idaboy JR.. Lipoic acid and dihydrolipoic acid. a comprehensive theoretical study of their antioxidant activity supported by available experimental kinetic data. J Chem Inf Model 2014;54:1642–52. PubMed

Estrada M, Pérez C, Soriano E, et al. . New neurogenic lipoic-based hybrids as innovative Alzheimer’s drugs with σ-1 agonism and β-secretase inhibition. Future Med Chem 2016;8:1191–207. PubMed

Rosini M, Simoni E, Bartolini M, et al. . Exploiting the lipoic acid structure in the search for novel multitarget ligands against Alzheimer’s disease. Eur J Med Chem 2011;46:5435–42. PubMed

Irannejad H, Amini M, Khodagholi F, et al. . Synthesis and in vitro evaluation of novel 1,2,4-triazine derivatives as neuroprotective agents. Bioorg Med Chem 2010;18:4224–30. PubMed

Shidore M, Machhi J, Shingala K, et al. . Benzylpiperidine-linked diarylthiazoles as potential anti-Alzheimer’s agents: synthesis and biological evaluation. J Med Chem 2016;59:5823–46. PubMed

Meena P, Nemaysh V, Khatri M, et al. . Synthesis, biological evaluation and molecular docking study of novel piperidine and piperazine derivatives as multi-targeted agents to treat Alzheimer’s disease. Bioorg Med Chem 2015;23:1135–48. PubMed

Ono K, Hasegawa K, Naiki H, Yamada M.. Curcumin has potent anti-amyloidogenic effects for Alzheimer’s beta-amyloid fibrils in vitro. J Neurosci Res 2004;75:742–50. PubMed

Poroikov VV, Filimonov DA, Ihlenfeldt W-D, et al. . PASS biological activity spectrum predictions in the enhanced open NCI database browser. J Chem Inf Comput Sci 2003;43:228–36. PubMed

De Strooper B. Proteases and proteolysis in Alzheimer disease: a multifactorial view on the disease process. Physiol Rev 2010;90:465–94. PubMed

Perry EK, Perry RH, Blessed G, Tomlinson BE.. Changes in brain cholinesterases in senile dementia of Alzheimer type. Neuropathol Appl Neurobiol 1978;4:273–7. PubMed

Guillozet AL, Smiley JF, Mash DC, Mesulam MM.. Butyrylcholinesterase in the life cycle of amyloid plaques. Ann Neurol 1997;42:909–18. PubMed

Grossberg GT. Cholinesterase Inhibitors for the Treatment of Alzheimer's disease: getting on and staying on. Curr Ther Res Clin Exp 2003;64:216–35. PubMed PMC

Pepeu G, Giovannini MG.. Cholinesterase inhibitors and memory. Chem Biol Interact 2010;187:403–8. PubMed

Dong H, Yuede CM, Coughlan CA, et al. . Effects of donepezil on amyloid-beta and synapse density in the Tg2576 mouse model of Alzheimer's disease. Brain Res 2009;1303:169–78. PubMed PMC

Morphy R, Rankovic Z.. Designed multiple ligands. An emerging drug discovery paradigm. J Med Chem 2005;48:6523–43. PubMed

Cavalli A, Bolognesi ML, Minarini A, et al. . Multi-target-directed ligands to combat neurodegenerative diseases. J Med Chem 2008;51:347–72. PubMed

Prati F, Cavalli A, Bolognesi ML. Navigating the chemical space of multitarget-directed ligands: from hybrids to fragments in Alzheimer's disease. Mol Basel Switz 2016;21:466. PubMed PMC

Panek D, Więckowska A, Wichur T, et al. . Design, synthesis and biological evaluation of new phthalimide and saccharin derivatives with alicyclic amines targeting cholinesterases, beta-secretase and amyloid beta aggregation. Eur J Med Chem 2017;125:676–95. PubMed

Wager TT, Hou X, Verhoest PR, Villalobos A.. Central nervous system multiparameter optimization desirability: application in drug discovery. ACS Chem Neurosci 2016;7:767–75. PubMed

Mezeiova E, Korabecny J, Sepsova V, et al. . Development of 2-methoxyhuprine as novel lead for Alzheimer’s disease therapy. Mol Basel Switz 2017;22:E1265. PubMed PMC

Dolles D, Nimczick M, Scheiner M, et al. . Aminobenzimida-zoles and structural isomers as templates for dual-acting butyrylcholinesterase inhibitors and hCB2 R ligands to combat neurodegenerative disorders. ChemMedChem 2016;11:1270–83. PubMed

Prati F, De Simone A, Bisignano P, et al. . Multitarget drug discovery for Alzheimer's disease: triazinones as BACE-1 and GSK-3β inhibitors. Angew Chem Int Ed Engl 2015;54:1578–82. PubMed

Wyss-Coray T, Rogers J.. Inflammation in Alzheimer Disease: a brief review of the basic science and clinical literature. Cold Spring Harb Perspect Med 2012;2:a006346. PubMed PMC

Is It the Twilight of BACE1 Inhibitors?